Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

Rhea-AI Summary

Senseonics (NASDAQ: SENS) received CE Mark approval for the Eversense 365 continuous glucose monitor, clearing commercialization across the EU and enabling planned launches in Germany, Italy, Spain, and Sweden in the coming months. The device is the first one-year implantable CGM, following FDA clearance and U.S. launch in 2024. The company says the approval expands its reachable EU patient population by over 30 million and positions Eversense 365 for integration with automated insulin delivery systems.

Positive

• CE Mark approval for Eversense 365 enables EU commercialization
• Expands EU total addressable market by over 30 million patients
• Planned launches in Germany, Italy, Spain, and Sweden
• Eversense 365 is the only one-year implantable CGM commercially cleared
• iCGM clearance in the U.S. supports AID system integration

Negative

• No glucose data generated when the transmitter is removed
• Initial European availability limited to select countries during rollout

News Market Reaction – SENS

+5.32% 2.0x vol

9 alerts

+5.32% News Effect

+2.9% Peak Tracked

-4.0% Trough Tracked

+$15M Valuation Impact

$306M Market Cap

2.0x Rel. Volume

On the day this news was published, SENS gained 5.32%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.9% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $306M at that time. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Sensor duration: 365 days CGM replacement interval: 10–14 days Sensor survivability: 12 months +4 more

7 metrics

Sensor duration 365 days Eversense 365 CGM sensor lifespan

CGM replacement interval 10–14 days Short-term CGM sensor change frequency cited for comparators

Sensor survivability 12 months Continuous sensor survivability period mentioned for Eversense 365

EU diabetes population over 30 million patients Estimated addressable diabetes population in the EU

Launch geographies 4 EU countries Planned launches in Germany, Italy, Spain and Sweden

Year referenced 2026 Management commentary on expected commercial progress in 2026

Trial timing second half of 2026 Planned completion timing for the Gemini trial

Market Reality Check

Price: $6.34 Vol: Volume 423,171 is slightl...

normal vol

$6.34 Last Close

Volume Volume 423,171 is slightly below the 20-day average of 453,064, suggesting no unusual trading activity ahead of this news. normal

Technical Shares at $6.82 are trading below the $9.09 200-day MA and sit well under the $28 52-week high.

Peers on Argus

Multiple medical device peers were also down (e.g., PACB -7.75%, BFLY -3.79%, DC...

Multiple medical device peers were also down (e.g., PACB -7.75%, BFLY -3.79%, DCTH -2.94%), but the momentum scanner did not flag a coordinated sector move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim revenue update	Positive	-1.5%	Preliminary Q4 and 2025 revenue records with strong 2026 growth guidance.
Jan 08	Product integration	Positive	+1.4%	First commercial patients using Eversense 365 integrated with twiist AID system.
Nov 10	Conference participation	Positive	+5.3%	Participation in Stifel 2025 Healthcare Conference with investor access and webcast.
Nov 10	Exchange transfer	Positive	+5.3%	Transfer of listing from NYSE American to Nasdaq Global Select Market.
Nov 05	Earnings report	Positive	+0.6%	Q3 2025 results with 90% revenue growth and improved gross profit and losses.

Pattern Detected

Recent news has mostly been followed by modest positive price reactions, with one notable divergence on strong preliminary revenue guidance.

Recent Company History

Over the past several months, Senseonics reported strong growth, including Q3 2025 revenue of $8.1M (up 90% YoY) and preliminary full‑year 2025 revenue of ~$35.2M with guidance for further expansion. The company executed a 1‑for‑20 reverse split and moved its listing to the Nasdaq Global Select Market. It also advanced commercialization of Eversense 365 and integration with Sequel’s twiist AID system. Today’s European CE Mark approval extends this commercialization trajectory beyond the U.S. into key EU markets.

Regulatory & Risk Context

Active S-3 Shelf · $300 million

Shelf Active

Active S-3 Shelf Registration 2025-08-06

$300 million registered capacity

An effective Form S-3 shelf allows Senseonics to issue up to $300 million in securities, including a $100 million ATM program, which could introduce dilution risk alongside added financing flexibility.

Market Pulse Summary

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with prior news behavior, where 4 of the last 5 announcements led to gains. CE Mark approval for Eversense 365 materially broadens the addressable EU market and adds to recent U.S. commercialization and integration milestones. However, an active shelf allowing up to $300 million in issuance and a history of capital needs could temper sustainability if investors anticipate future dilution.

Key Terms

continuous glucose monitoring, ce mark, eu medical device regulation (mdr), integrated cgm (icgm), +3 more

7 terms

continuous glucose monitoring medical

"implantable continuous glucose monitoring (CGM) systems for people with diabetes"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

ce mark regulatory

"today announced CE Mark approval for the Eversense® 365 CGM system"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

eu medical device regulation (mdr) regulatory

"submission was prepared in compliance with the EU Medical Device Regulation (MDR)"

A set of European Union rules that sets safety, testing and approval requirements for medical devices sold in Europe, from bandages to implantable equipment. Think of it as a strict building code and inspection system for health products: manufacturers must prove safety and effectiveness, maintain ongoing monitoring, and get an EU safety mark before selling. Investors care because compliance affects a device maker’s ability to sell in Europe, costs, timelines, liability and competitive position.

integrated cgm (icgm) medical

"Eversense 365 has been cleared as an integrated CGM (iCGM) system in the United States"

An integrated continuous glucose monitor (iCGM) is a wearable sensor that measures blood sugar levels every few minutes and automatically shares that data with other devices like insulin pumps, smartphones or medical software. For investors, iCGMs matter because they shift diabetes care from occasional checks to continuous, connected management, creating steady device sales, subscription data services, and higher barriers to entry through regulatory approvals and device compatibility—factors that can drive revenue and adoption.

automated insulin delivery (aid) system medical

"including insulin pumps as part of an automated insulin delivery (AID) system"

An automated insulin delivery (AID) system is a medical device that links a continuous glucose monitor, an insulin pump, and a computerized control algorithm to automatically adjust insulin doses throughout the day, like a thermostat for blood sugar. It matters to investors because AID systems can drive steady device and consumable sales, create long-term customer stickiness, and face clear regulatory and reimbursement hurdles that affect market size, revenue predictability, and competitive advantage.

transmitter technical

"The only CGM with a removable transmitter which can be easily taken on and off"

A transmitter is the device or system that sends data, signals, or other information from one place to another — similar to a radio tower beaming a song to many radios or a courier delivering a package. For investors, the presence, quality, regulatory approval and market reach of a transmitter matter because they affect a product’s reliability, customer adoption, revenue potential and compliance risk; weak or uncertified transmitters can limit sales or trigger regulatory problems.

sensor medical

"A tiny sensor that rests comfortably under the skin means that it cannot be knocked off"

A sensor is a device that detects and converts physical or chemical conditions—such as temperature, motion, pressure, chemical levels, or biological signals—into measurable electronic data. Think of it as a thermometer or smoke alarm that turns real-world changes into numbers a system can read. For investors, sensors matter because they are core to product performance, regulatory compliance, and recurring revenue from hardware, software, and data services, affecting a company’s market potential and risk profile.

AI-generated analysis. Not financial advice.

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense^® 365 CGM system.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.

The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and is now approved for commercialization in the European Union (EU). The Company expects to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months.

“European approval for Eversense 365 represents the latest achievement in our long-term growth strategy for Senseonics and expands our total addressable market by over 30 million patients living with diabetes in the EU. As we take full ownership of all commercial activities for Eversense 365, we expect our expansion in Europe to contribute to top-line revenue growth, while offering a single year-long CGM solution to glucose monitoring,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “2026 will be an exciting year as we drive commercial progress in the U.S. and Europe, expect the impact of the integration with Sequel’s twiist™ Automated Insulin Delivery (AID) System in the U.S., and simultaneously await planned completion of the Gemini trial in the second half of the year.”

The Eversense 365 CGM System has been designed to deliver key improvements from currently available CGMs:

• Longest lasting CGM: The only CGM with a 365-day sensor means no frequent sensor changes, and only one insertion and one “Day 1” every year, compared to every 10-14 days with short-term CGM systems
• Most dependable CGM: Sensor survivability across 12 months reduces the burden of data interruptions from frequent short-term CGM sensor failures or changes^{1, 2, 3}
• No more wasted sensors: A tiny sensor that rests comfortably under the skin means that it cannot be knocked off, minimizing the inconvenience and cost of regular replacements
• Alerts that can be trusted: Exceptional accuracy consistently for one year⁴ and almost no false alerts from compression lows during the night⁵
• Maximum comfort: A gentle silicone-based adhesive that can be changed daily and causes almost no skin reactions⁶
• More freedom: The only CGM with a removable transmitter which can be easily taken on and off^† without wasting a sensor or adding a warm up period
• Improved discretion: On-body vibration alerts keep patients notified even when their mobile phone is out of sight
  

Eversense 365 has been cleared as an integrated CGM (iCGM) system in the United States, indicating that it can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system. Eversense 365 is exceptionally well suited to address common limitations⁷ of AID systems, and the Company is advancing partnership discussions with various pump manufacturers.

^† There is no glucose data generated when the transmitter is removed
¹Senseonics. (2024) Eversense 365 User Guide.
² Abbott. (2024) Freestyle Libre 3 User Guide ART49385-001 Rev. A 04/24
³ Dexcom (2024) G7 User Guide AW00078-10 Rev 003 MT-00078-10
⁴ Data on file
⁵ Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206. doi:10.1089/dia.2017.0142
⁶ Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. Diabetes Technology & Therapeutics, 22(1), 48–52.
⁷ Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023;66(1):3-22. doi:10.1007/s00125-022-05744-z

About Eversense

Eversense 365 is developed by Senseonics and, as the only implantable CGM available, offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM.

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including expected sales growth, the expansion of the addressable market, the timing of the European launch of Eversense 365, business expansion in Europe, the integration with the Sequel twiist AID system, expected progress of the Gemini clinical trial, advancing partnership discussions for AID solutions, and the potential benefits and accuracy related to using the the Eversense 365, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the commercialization, launch and sale of new products, uncertainties inherent executing corporate acquisions and the transition of commercial activities from Ascensia to Senseonics, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics’ and its partners’ activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and future reports filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

FAQ

What did Senseonics (SENS) announce about Eversense 365 on January 29, 2026?

Senseonics announced CE Mark approval for Eversense 365, permitting EU commercialization. According to the company, launches are planned in Germany, Italy, Spain, and Sweden in the coming months and EU patient reach expands by over 30 million.

How does the Eversense 365 approval affect Senseonics (SENS) market opportunity?

The approval meaningfully increases European reach by a quantified patient base. According to the company, the CE Mark expands the total addressable market in the EU by over 30 million patients, supporting top-line growth expectations.

Will Eversense 365 integrate with automated insulin delivery systems for SENS shareholders?

Eversense 365 has iCGM clearance in the U.S., enabling integration with compatible AID systems. According to the company, partnership discussions with pump manufacturers are advancing to support AID integration.

When will Eversense 365 be available in European markets for SENS investors?

Senseonics expects staged launches in select EU countries in the coming months. According to the company, initial commercialization will begin in Germany, Italy, Spain, and Sweden following CE Mark approval.

What are known product limitations of Eversense 365 that SENS investors should note?

Eversense 365 requires a removable transmitter and has a specific data limitation when detached. According to the company, no glucose data is generated while the transmitter is removed, which affects real-time monitoring.